Circulation Reports · Sep 2, 2026
Prognostic Implications of Clinically Attributed Left Atrial Enlargement Subtypes in Patients Undergoing Transcatheter Aortic Valve Implantation
By Sato T, Ito A, Kitagawa Y et al.
BACKGROUND: Left atrial enlargement (LAE) is common in patients undergoing transcatheter aortic valve implantation (TAVI), but its prognostic significance may vary according to the clinical drivers of atrial remodeling. We examined whether prognostic factors differ by clinically attributed LAE subtype in patients undergoing TAVI with preserved left ventricular ejection fraction (LVEF). METHODS AND RESULTS: We retrospectively analyzed 317 consecutive patients with symptomatic severe aortic stenosis (AS) undergoing TAVI who had preserved LVEF and LAE. Patients were classified as AS-associated LAE (no atrial fibrillation [AF] and <moderate mitral regurgitation [MR]) or AF/MR-associated LAE (AF and/or ≥moderate MR). The primary endpoint was all-cause death. During a median follow-up of 2.7 years, 69 patients (21.8%) died. The all-cause mortality rate was higher in the AF/MR-associated group than in the AS-associated LAE group (30.7% vs. 19.0%; log-rank P<0.01), but this association was attenuated after adjustment for eGFR, log-BNP, and LAVI. In the AS-associated LAE group, higher log-BNP (hazard ratio (HR) 1.45, 95% confidence interval (CI) 1.06-1.98), higher E/e' (HR 1.03, 95% CI 1.01-1.06), and lower TAPSE (HR 0.89, 95% CI 0.81-0.99) predicted death. In the AF/MR-associated LAE group, lower eGFR (HR 0.96, 95% CI 0.93-1.00) and higher log-BNP (HR 1.98, 95% CI 1.09-3.59) predicted death after adjustment for age. Interactions were significant for eGFR and E/e'. CONCLUSIONS: Prognostic markers after TAVI differ by clinically attributed LAE subtype, supporting subtype-informed risk stratification.
doi.org/10.1253/circrep.cr-26-0181Open accessPubMed 43011164Biomarkers